1. Prognostic impact of chromogranin A in patients with acute heart failure
- Author
-
Kim, Hong Nyun, Yang, Dong Heon, Park, Bo Eun, Park, Yoon Jung, Kim, Hyeon Jeong, Jang, Se Yong, Bae, Myung Hwan, Lee, Jang Hoon, Park, Hun Sik, Cho, Yongkeun, and Chae, Shung Chull
- Subjects
Medicine (General) ,endocrine system ,Prognosis prediction ,medicine.medical_specialty ,medicine.drug_class ,Composite event ,heart failure ,Gastroenterology ,R5-920 ,Internal medicine ,Natriuretic peptide ,Medicine ,In patient ,Adverse effect ,biology ,business.industry ,Mortality rate ,chromogranin a ,biomarkers ,Chromogranin A ,medicine.disease ,Heart failure ,biology.protein ,Original Article ,prognosis ,business - Abstract
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p
- Published
- 2021